CN1869216A - Expression method of recombination human bone formation protein-2 - Google Patents
Expression method of recombination human bone formation protein-2 Download PDFInfo
- Publication number
- CN1869216A CN1869216A CN 200610032800 CN200610032800A CN1869216A CN 1869216 A CN1869216 A CN 1869216A CN 200610032800 CN200610032800 CN 200610032800 CN 200610032800 A CN200610032800 A CN 200610032800A CN 1869216 A CN1869216 A CN 1869216A
- Authority
- CN
- China
- Prior art keywords
- hbmp
- carrier
- renaturation
- gene
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
This invention discloses a expressing method of human bone recombination to form albumen-2. It includes the synthesis of aiming gene hBMP-2 gene synthesis, hBMP-2 gene and carrier are cut by Nde I and BamH I, the carrier is recombined, host germ is transferred to construct hBMP-2 gene engineering germ, then hBMP-2 gene engineering germ is cultured, then occlusion body salvation is got after the occlusion body is separated, washed and dissolved. Then it is purified, ultrafiltrated, dialyzed and frozen dry to get albumen-2. The technique is simple, cost is low, output is high, activity is good, its renaturation can reach 60 percent, so it has great superiority in industrialization generating, so it is propitious to large scale generation.
Description
Technical field
The present invention relates to the genetically engineered field, relate in particular to a kind of recombination human bone shaping protein-2 expression method.
Background technology
(human bone morphorgenetic protein-2 is bone morphogenetic protein family a member hBMP-2) to Human Bone Morphogenetic Proteins-4-2, belongs to the TGF-beta superfamily, and it is by two 114 homodimers that amino-acid residue constitutes that active sophisticated hBMP-2 is arranged.HBMP-2 is extensive in the physiological function of human body, all play an important role at the aspects such as growth, differentiation, chemotaxis and apoptosis of regulating cell, can promote the healing of big area bone injury in conjunction with the human compatibility tissue engineering material, and can be widely used in tooth reparation, beauty and shaping, thereby be with a wide range of applications clinically.
Serve as the main rhBMP-2 of production with the animal cell expression system abroad, the cost height yields poorly, and is active good, normally glycosylation.The listing of U.S. FDA approved is used for spinal fusion.The used escherichia coli expression rhBMP-2 of domestic East China gene studies, it is a purifying after inclusion body stage elder generation's renaturation, annealing efficiency is lower like this, and is active bad.
Summary of the invention
The objective of the invention is to overcome the problem that existing Human Bone Morphogenetic Proteins-4-2 production method exists, the Human Bone Morphogenetic Proteins-4's-2 that a kind of cost is low, annealing efficiency is high, activity is good expression method is provided.
To achieve these goals, the present invention adopts following technical scheme:
A kind of recombination human bone shaping protein-2 expression method comprises the steps:
(1) goal gene hBMP-2's is synthetic;
(2) double digestion hBMP-2 gene and carrier connect the structure recombinant vectors, transform the host bacterium, make up the hBMP-2 genetic engineering bacterium;
(3) cultivate the hBMP-2 genetic engineering bacterium, separate, clean, dissolve inclusion body and obtain solubilization of inclusion bodies liquid;
(4) purifying inclusion body;
(5) renaturation;
(6) ultrafiltration, dialysis, freeze-drying obtain recombination human bone shaping protein-2.
Synthesizing of above-mentioned steps (1) described goal gene: design upstream primer ATCGCATATGGGCCTAACCTTCTTTTGAAGCTTATTCAA, downstream primer ACGTGGATCCCTATTAGCAACACCCACAACCCT; With people's embryo cDNA library is template, RT-PCR amplification hBMP-2 gene, and the condition of RT-PCR is 94 ℃, 5min, 94 ℃, 30s, 60 ℃, 30s, 72 ℃, 30s, 35 circulations, 72 ℃, 10min.
The described carrier of above-mentioned steps (2) is pET35b (+) or PBV220.When carrier was pET35b (+), the used restriction enzyme of double digestion was Nde I, BamH I; When carrier was PBV220, the used restriction enzyme of double digestion was BamH I, EcoR I.
The described host bacterium of above-mentioned steps (2) is intestinal bacteria.
The substratum of the described cultivation of above-mentioned steps (3) hBMP-2 genetic engineering bacterium is the LB substratum, and culture temperature was 30~32 ℃ when carrier was pET35b (+); Culture temperature was 30 ℃ when carrier was PBV220, and inducing temperature is 42 ℃.
The described separation of above-mentioned steps (3), cleaning, dissolving inclusion body are with the engineering bacteria ultrasonication, and centrifugal collecting precipitation cleans with solution 1, with solution 2 dissolvings; Described solution 1 is 2%Triton X-100,50mmol Tris-HCl, pH7.4,1mmol EDTA; Described solution 2 is 8M urea, 50mmol Tris, pH7.0,1mmol EDTA, 0.1M beta-mercaptoethanol.
The described purifying inclusion body of above-mentioned steps (4) is to adopt the anion-exchange chromatography purifying, and required filler is DEAE, PEI or QAE; Adsorption conditions is that pH is between 7~9; Elution requirement is for salt or change pH, and salt concn is 0.1~0.4mol/LNaCl, and pH is between 7~9.
The described renaturation of above-mentioned steps (5) is to adopt the dilution method renaturation, and renaturation solution is: pH10.5,50mmol/L yellow soda ash, 1mol/L sodium-chlor, 20% glycerine, 0.5 μ mol/LCuCl
2With the 1mmol/L dithiothreitol (DTT).
The described ultrafiltration of above-mentioned steps (6) is to adopt molecular weight 10000 daltonian ultra-filtration membrane ultrafiltration, and described dialysis is to adopt semi-permeable membranes that mass percent 0.1% acetic acid is dialysed.
Compared with prior art, the present invention has following beneficial effect:
The rhBMP-2 of escherichia coli expression exists with the inclusion body form, sophisticated activated hBMP-2 structure more complicated, it is carried out relatively difficulty of external change renaturation, the present invention is passing through on the basis of escherichia coli high-level expression rhBMP-2, the various factors that influences its annealing efficiency has been carried out qualitative, quantitative research, determined the comparatively suitable method of the external change renaturation of recombination human bone shaping protein-2, its annealing efficiency is reached about 50%~60%, the ED of rhBMP-2 after the renaturation
50Be up to 0.71 μ g/ml, be fit to carry out industrialization.Technology of the present invention is easy, and cost is low, the output height, and active good, renaturation yield can reach about 60%, has advantage on industrialization is produced, and is suitable for scale operation.
Description of drawings
Fig. 1 is the design of graphics of pET/hBMP-2 expression plasmid;
Fig. 2 is expression and the purifying figure of rhBMP-2;
Fig. 3 is the non-reduced and reductive SDS-PAGE figure of rhBMP-2 dimer after the renaturation;
Fig. 4 be after the renaturation rhBMP-2 at the mensuration figure of C2C12 cell neutral and alkali phosphatase activity.
Wherein, among Fig. 1,1 is pET35b (+), and 2 is NdeI+BamHI, and 3 is the PCR product, and M is λ-Hind III; Among Fig. 2,1 is inductive bacterial protein not, and 2 is to induce the back bacterial protein, and 3 be the preceding purified rhBMP-2 of renaturation, and M is albumen marker; Among Fig. 3,1 is non-reduced electrophoresis, and 2 are the reduction electrophoresis, and 3 is the rhBMP-2 dimer behind the purifying, and 4 is reference substance, and M is albumen marker.
Embodiment
(1) design upstream primer ATCG
CATATGGGCCTAACCTTCTTTTGAAGCTTATTCAA, downstream primer ACGT
GGATCCCTATTAGCAACACCCACAACCCT; With people's embryo cDNA library is template, pcr amplification BMP-2 gene, and the PCR condition is: 94 ℃, 5min, 94 ℃, 30s, 60 ℃, 30s, 72 ℃, 30s, 35 circulations, 72 ℃, 10min.1.5% agarose gel electrophoresis, the visible one obvious band at the 342bp place matches with estimating the product size.(Fig. 1)
(2) cut the hBMP-2 gene of glue recovery behind pcr amplification, behind hBMP-2 and pET35b (+) behind the NdeI+BamHI double digestion, connect according to ordinary method, and be transformed into DH5 α competent cell.The several clones of random choose on flat board, the extracting plasmid is cut the evaluation recon with the NdeI+BamHI enzyme, and recon is by the accuracy of the definite sequence of company's order-checking simultaneously, and sequencing result is consistent with design.
(3) select the highest recon of expression amount, by 1% inoculum size its access is equipped with in the culturing bottle of 5mlLB substratum, spend the night, be forwarded in 500ml LB substratum by 1% next day, is cultured to OD
600=0.2, add IPTG to final concentration 1mM, continue to cultivate 4 hours.8000 rev/mins of centrifugal collection thalline of 30min, PBS is resuspended, ultrasonication thalline, 8000 rev/mins of centrifugal collection inclusion bodys of 30min.
(4) inclusion body is cleaned with solution 1,8000 rev/mins of 30min are centrifugal, collecting precipitation, and dissolve with solution 2.Described solution 1 is 2%Triton X-100,50mmol/Ltris-HCl, 1mmol/LEDTA, pH7.0; Described solution 2 is 8mol/L urea, 50mmol/Ltris-HCl, 1mmol/LEDTA, 0.1mol/L beta-mercaptoethanol.
(5) with DEAE-Sephorase (Pharmacia company product) filler dress post (30cm * 3cm), with 20mmol/LPBS+8M urea (pH 8.0) balance, with sample on the sample to be purified, applied sample amount is 30mL, wash to baseline with balance liquid after the completion of the sample, use 0.25mol/LNaCl+8M urea+20mmol/LPBS (pH 7.0) wash-out pillar again, collect elution peak.(Fig. 2)
(6) above-mentioned elution peak is collected liquid by the dilution method renaturation, renaturation solution is: pH10.5,50mnol/L yellow soda ash, 1mol/L sodium-chlor, 20% glycerine, 0.5 μ mol/LCuCl
2And 1mmol/L dithiothreitol (DTT).Final concentration of protein is 0.2mg/ml during renaturation, and the renaturation time is 48 hours.
(7) albumen after the renaturation is the ultra-filtration membrane ultrafiltration that 10000 roads pause by molecular weight, then to after the dialysis of mass percent 0.1% acetic acid, and freeze-drying.(Fig. 3)
(8) the cell method is measured the biological activity of the C2C12 cell induction being expressed ALP, and method is with reference to relevant document.Be higher than contrast through the rhBMP-2 of renaturation activity.RhBMP-2 activity after the renaturation is respectively 0.71 μ g/ml, reference substance (R﹠amp; D systems) is 1.2 μ g/ml.(Fig. 4)
Test shows that the present invention is by unique technology, and easy method becomes a reality the scale operation of BMP-2.Escherichia coli expression BMP-2, cost is low, and the output height because our technology renaturation yield can reach about 60%, therefore, has advantage on industrialization is produced.
Claims (9)
1, a kind of recombination human bone shaping protein-2 expression method is characterized in that comprising the steps:
(1) goal gene hBMP-2's is synthetic;
(2) double digestion hBMP-2 gene and carrier connect the structure recombinant vectors, transform the host bacterium, make up the hBMP-2 genetic engineering bacterium;
(3) cultivate the hBMP-2 genetic engineering bacterium, separate, clean, dissolve inclusion body and obtain solubilization of inclusion bodies liquid;
(4) purifying inclusion body;
(5) renaturation;
(6) ultrafiltration, dialysis, freeze-drying obtain recombination human bone shaping protein-2.
2, the method for claim 1, it is characterized in that synthesizing of step (1) described goal gene: design upstream primer ATCGCATATGGGCCTAACCTTCTTTTGAAGCTTATTCAA, downstream primer ACGTGGATCCCTATTAGCAACACCCACAACCCT; With people's embryo cDNA library is template, RT-PCR amplification hBMP-2 gene, and the condition of RT-PCR is 94 ℃, 5min, 94 ℃, 30s, 60 ℃, 30s, 72 ℃, 30s, 35 circulations, 72 ℃, 10min.
3, the method for claim 1 is characterized in that the described carrier of step (2) is pET35b (+) or PBV220; When carrier was pET35b (+), the used restriction enzyme of double digestion was Nde I, BamH I; When carrier was PBV220, the used restriction enzyme of double digestion was BamH I, EcoR I.
4, the method for claim 1 is characterized in that the described host bacterium of step (2) is intestinal bacteria.
5, the method for claim 1 is characterized in that the substratum of the described cultivation of step (3) hBMP-2 genetic engineering bacterium is the LB substratum; Culture temperature was 30~32 ℃ when carrier was pET35b (+); Culture temperature was 30 ℃ when carrier was PBV220, and inducing temperature is 42 ℃.
6, the method for claim 1 is characterized in that the described separation of step (3), cleaning, dissolving inclusion body are with the engineering bacteria ultrasonication, and centrifugal collecting precipitation cleans with solution 1, with solution 2 dissolvings; Described solution 1 is 2%Triton X-100,50mmol Tris-HCl, pH7.4, and 1mmol EDTA, described solution 2 is 8M urea, 50mmol Tris, pH7.0,1mmol EDTA, 0.1M beta-mercaptoethanol.
7, the method for claim 1 is characterized in that the described purifying inclusion body of step (4) is to adopt the anion-exchange chromatography purifying, and required filler is DEAE, PEI or QAE; Adsorption conditions is that pH is between 7~9; Elution requirement is for salt or change pH, and salt concn is 0.1~0.4mol/LNaCl, and pH is between 7~9.
8, the method for claim 1 is characterized in that the described renaturation of step (5) is to adopt the dilution method renaturation, and renaturation solution is: pH10-11,50mnol/L yellow soda ash, 1mol/L sodium-chlor, 5-20% glycerine, 0.1-1 μ mol/LCuCl
2And 1-10mmol/L dithiothreitol (DTT).
9, the method for claim 1 is characterized in that the described ultrafiltration of step (6) for adopting molecular weight 10000 daltonian ultra-filtration membrane ultrafiltration, and described dialysis is to adopt semi-permeable membranes that 0.1% acetic acid is dialysed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100328007A CN100410371C (en) | 2006-05-13 | 2006-05-13 | Expression method of recombination human bone formation protein-2 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100328007A CN100410371C (en) | 2006-05-13 | 2006-05-13 | Expression method of recombination human bone formation protein-2 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1869216A true CN1869216A (en) | 2006-11-29 |
CN100410371C CN100410371C (en) | 2008-08-13 |
Family
ID=37442995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100328007A Expired - Fee Related CN100410371C (en) | 2006-05-13 | 2006-05-13 | Expression method of recombination human bone formation protein-2 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100410371C (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1230436A (en) * | 1998-12-15 | 1999-10-06 | 中国人民解放军第四军医大学 | Soluble recombined human bone formation protein 2 used in treating hemospoietic dysfunction and function damage |
CN1333295A (en) * | 2000-07-11 | 2002-01-30 | 韩延 | Reconbination human bone morphogenetic protein-2truncated mutant and preparation method thereof |
DE10059336A1 (en) * | 2000-11-29 | 2002-06-13 | Scil Proteins Gmbh | Production of recombinant BMP-2 |
CN1215171C (en) * | 2001-04-21 | 2005-08-17 | 杭州华东医药(集团)公司基因技术研究所 | Process for preparing truncated recombinant human bone morphorgenetic protein-2 mature peptide |
CN100402646C (en) * | 2005-07-07 | 2008-07-16 | 徐放 | Method of producing recombination human bone morphopoiesis protein |
-
2006
- 2006-05-13 CN CNB2006100328007A patent/CN100410371C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN100410371C (en) | 2008-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110845603B (en) | Human collagen 17-type polypeptide, production method and use thereof | |
CN111944057B (en) | Recombinant human collagen peptide and application thereof | |
CN111454350B (en) | Recombinant fibronectin mutant and application thereof | |
CN104540846B (en) | Methods for refolding g-csf from inclusion bodies | |
CN113621053A (en) | Recombinant human collagen and preparation method and application thereof | |
CN110950967B (en) | Anti-human serum albumin nano antibody and IL-2 fusion protein and preparation method thereof | |
EP3985019A1 (en) | Recombinant human collagen and construction method therefor | |
CN102191256A (en) | Hypha mycin gene and karyogamy gene-engineering bacteria thereof | |
CN101092618B (en) | Method for preparing enzyme of dissolving staphylococcal bacteria, its derivative, and method for preparing the derivative | |
RU2354702C2 (en) | RECOMBINANT PLASMID DNA pHINS11 CODING HYBRID PROTEIN-HUMAN INSULIN PRECURSOR, Escherichia coli CELL, TRANSFORMED WITH RECOMBINANT PLASMID DNA pHINS11, Escherichia coli BACTERIA STRAIN JM109/pHINS11 - PRODUCER OF HYBRID PROTEIN-HUMAN INSULIN PRECURSOR, AND METHOD OF OBTAINING HUMAN INSULIN | |
CN111423516B (en) | Protein and application thereof in wound repair and bacteriostasis | |
CN105177033A (en) | Method for preparing alkaline fiber cell growth factors through pSUMO system | |
CN109776653B (en) | Human serum albumin adhesion peptide and application thereof | |
CN106755042A (en) | A kind of bioactive micro peptide preparation method based on combination self cleavage with albumen support | |
CN100410371C (en) | Expression method of recombination human bone formation protein-2 | |
CN101914546B (en) | Amphioxus saccharide pattern-recognition molecule Bjfcn1 gene and application thereof | |
CN108117599A (en) | The recombination expression and purification process of Ssm6a and its fusion protein used | |
CN102260697A (en) | Process for preparing human beta interferon through fusion expression and recombination | |
CN102586257A (en) | Sika deer IGF (Insulin-like Growth Factor)-1 polypeptide and preparation method thereof | |
CN101766810A (en) | Medical preparation containing recombinant human granulocytecolony stimulating factor | |
CN1142281C (en) | Preparation of recombined erythropoietin preparation | |
CN1257916C (en) | Parathyroid hormone analog and its preparing process by recombination | |
CN102558356A (en) | Human proinsulin fusion protein and preparation method of human insulin | |
CN102585013B (en) | Fusion protein containing omega interferon and method for preparing same | |
CN102242124A (en) | Modified Keratinocyte growth factor gene and its expression in yeast |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080813 Termination date: 20110513 |